2026-10-19T00:37:15Zhttps://ebyu-rdlopen.rawdatalibrary.net/oai/request

oai:ebyu-rdlopen.rawdatalibrary.net:ebyu/121112026-10-18T21:13:20Zopenairedrivercom_ebyu_10000col_ebyu_10001

Effectiveness of Inactivated and mRNA COVID-19 Vaccines Against SARS-CoV-2 Infection, Severe Disease and Mortality in the Geriatric PopulationGenç Bahçe, YaseminAcer, ÖmerÖzüdoğru, OsmanAgedCOVID-19COVID-19 VaccinesHumansmRNA VaccinesRNA, MessengerSARS-CoV-2bnt 162b 2C reactive proteincoronavacD dimerferritintozinameranvaccinemessenger RNARNA vaccineSARS-CoV-2 vaccineArticlecomparative effectivenesscontrolled studycoronavirus disease 2019disease coursedisease severitydrug efficacyfemaleferritin blood levelfollow upgeriatric patienthospitalizationhumanOlder age (>60 years) has been identified as the main risk factor for COVID-19. In this study, we aimed to evaluate the efficacy of Pfizer–BioNTech and CoronaVac vaccines against COVID-19 infection, serious illness, and mortality in the geriatric population. We found that 2 doses of CoronaVac vaccine were ineffective in protecting against COVID-19 infection in people over 65 years of age, while the vaccine efficacy (VE) of the mRNA vaccine against COVID-19 was 80% (95% CI 70–87). The VE of full vaccination with BioNTech was 89% (95% CI 53–97) against hospitalization, 79% (95% CI 0–97) against death, and 79% (95% CI 0–97) against intensive care unit (ICU) admission. However, the VE of full vaccination with CoronaVac was 50% (95% CI 33–63) against hospitalization, 53% (95% CI 26–70) against ICU admission, and 56% (95% CI 30–73) against death. In conclusion, we found that the mRNA vaccine has higher efficacy against severe COVID-19 infection and mortality in the geriatric population than the inactivated vaccine. Booster doses of vaccines should be considered in increasing the effectiveness of inactivated vaccines. Given the potential of SARS-CoV-2 mutations evading vaccination protection and the risk of reduced immunity over time, regular monitoring of vaccine effectiveness in the real world is critical. © 2023, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.Springer2023Articlehttps://rdlopen.rawdatalibrary.net/r/ebyu/12111https://doi.org/10.1007/s00284-023-03322-z0343-8651enCurrent Microbiologyinfo:eu-repo/semantics/openAccessinfo:eu-repo/semantics/articlehttps://ebyu-rdlopen.rawdatalibrary.net/tr/items/ebyu/12111